© 2020 MJH Life Sciences, Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Breast Cancer
Leronlimab Shows Statistically Significant Improvement in Efficacy Outcome in Mild-to-Moderate COVID-19
August 12, 2020
Leronlimab, demonstrated improvement in total clinical symptom score at day 3 in patients with mild-to-moderate symptoms from coronavirus disease 2019.
Frontline Atezolizumab Plus Paclitaxel Misses Primary End Point in TNBC Trial
August 07, 2020
The phase 3 IMpassion131 trial investigating atezolizumab plus paclitaxel versus placebo plus paclitaxel did not its primary end point of progression-free survival and was not statistically significant in the first line for patients with metastatic triple-negative breast cancer who had PD-L1-positive disease.
Targeted Therapy in Early-Stage HER2+ Breast Cancer
July 31, 2020
Experts from Sarah Cannon Research Institute talk about the expanding role of targeted treatment options in early HER2+ breast cancer.
FDA Approval Being Considered for Neoadjuvant/Adjuvant Pembrolizumab +/- Chemo in Early TNBC
July 30, 2020
The FDA has accepted a supplemental Biologics License Application submitted for neoadjuvant pembrolizumab combined with chemotherapy and adjuvant pembrolizumab monotherapy for the treatment of patients with high-risk early-stage triple-negative breast cancer.
Pembrolizumab Plus Chemotherapy on the Road to FDA Approval for mTNBC, Granted Priority Review
July 30, 2020
The FDA accepted a supplemental Biologics License Application for and granted Priority Review to pembrolizumab in combination with chemotherapy, which is intended for the treatment of patients with locally recurrent unresectable or metastatic triple-negative breast cancer whose tumors express PD-L1.
FDA Approves Trastuzumab Companion Diagnostic for Detection of HER2 in Breast Cancer
July 30, 2020
The FDA has approved the Ventana HER2 Dual ISH DNA Probe Cocktail assay as a companion diagnostic for trastuzumab and for the detection of the HER2 biomarker in patients with breast cancer.
Veliparib Leads to PFS Boost in Certain Breast Cancer Subsets
July 24, 2020
“In both subgroups, the benefit of veliparib was durable, with an increased probability of remaining progression free at 2 and 3 years compared with placebo,”
Exploring Adjuvant Endocrine Therapy in the Breast Cancer Setting
July 22, 2020
Terry P. Mamounas, MD, MPH, discusses the use of extended adjuvant therapy for patients with breast cancer and how the landscape is evolving.
Breast, Ovarian Screening Questionnaire Reveals Just 1 in 5 Women Meet NCCN Criteria for Genetic Testing
July 21, 2020
A pathogenic germline mutation rate of about 5% has been identified in women who had a family history of breast or ovarian cancer but no personal history of either disease.
Precision Medicine Will Drive New Standards of Care in the Post–COVID-19 World
July 16, 2020
Once the impact of COVID-19 begins to minimize and activities settle into a “new normal,” efforts to expand precision medicine across many diseases will resume.